Scroll

thioguanine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2632	154-42-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: 6-Thioguanine thioguanine tioguanine	An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. Molecular weight: 167.19 Formula: C5H5N5S CLOGP: -1.70 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 79.09 ALOGS: -2.31 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

6-Thioguanine
thioguanine
tioguanine

An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.

Molecular weight: 167.19
Formula: C5H5N5S
CLOGP: -1.70
LIPINSKI: 0
HAC: 5
HDO: 3
TPSA: 79.09
ALOGS: -2.31
ROTB: 0

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	30 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
t_half (Half-life)	24.35 hours	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	2.89 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	15.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.83 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI

Showing 1 to 7 of 7 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Jan. 18, 1966	FDA	ASPEN GLOBAL INC

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	305.87	50.73	102	970	118347	63369603
Haematotoxicity	233.30	50.73	49	1023	9327	63478623
Venoocclusive disease	70.11	50.73	14	1058	2044	63485906
Staphylococcal sepsis	65.20	50.73	17	1055	8111	63479839
Toxic neuropathy	62.38	50.73	10	1062	418	63487532

Showing 1 to 5 of 5 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	602.34	36.70	244	1881	136605	34818201
Haematotoxicity	292.83	36.70	73	2052	8121	34946685
Venoocclusive liver disease	94.48	36.70	30	2095	7936	34946870
Febrile bone marrow aplasia	81.42	36.70	27	2098	8182	34946624
Osteonecrosis	76.13	36.70	30	2095	14860	34939946
Venoocclusive disease	43.27	36.70	13	2112	2854	34951952
Facial paresis	42.48	36.70	13	2112	3036	34951770
Pancytopenia	41.47	36.70	39	2086	95118	34859688
Periorbital infection	39.21	36.70	7	2118	150	34954656

Showing 1 to 9 of 9 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	850.99	36.13	320	2758	230679	79510631
Haematotoxicity	524.29	36.13	121	2957	15398	79725912
Venoocclusive liver disease	117.70	36.13	35	3043	11736	79729574
Venoocclusive disease	94.17	36.13	24	3054	4549	79736761
Osteonecrosis	84.44	36.13	35	3043	31060	79710250
Pancytopenia	74.48	36.13	57	3021	165688	79575622
Glioma	56.44	36.13	11	3067	611	79740699
Staphylococcal sepsis	51.84	36.13	20	3058	14706	79726604
Toxic neuropathy	45.83	36.13	10	3068	970	79740340
Facial paresis	44.82	36.13	14	3064	5512	79735798

Showing 1 to 10 of 17 entries

Previous1 2Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L01BB03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ANTIMETABOLITES Purine analogues
CHEBI has role	CHEBI:35221	antimetabolite
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:149553	anticoronaviral drug
MeSH PA	D000963	Antimetabolites
MeSH PA	D000964	Antimetabolites, Antineoplastic
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D009676	Noxae

Showing 1 to 8 of 8 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Acute myeloid leukemia, disease	indication	91861009
Acute lymphoid leukemia	off-label use	91857003	DOID:9952
Hyperbilirubinemia	contraindication	14783006	DOID:2741
Obstruction of bile duct	contraindication	30144000
Hyperuricemia	contraindication	35885006	DOID:1920
Portal vein obstruction	contraindication	57348003
Acute infectious disease	contraindication	63171007
Leukopenia	contraindication	84828003	DOID:615
Bleeding	contraindication	131148009
Liver function tests abnormal	contraindication	166603001

Showing 1 to 10 of 20 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.96	acidic
pKa2	10.93	acidic
pKa3	1.72	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Inosine-5'-monophosphate dehydrogenase 2	Enzyme	P12268	IMDH2_HUMAN	INHIBITOR			WOMBAT-PK	CHEMBL
Inosine-5'-monophosphate dehydrogenase 1	Enzyme	P20839	IMDH1_HUMAN	INHIBITOR			WOMBAT-PK	CHEMBL
Multidrug resistance-associated protein 5	Transporter	O15440	MRP5_HUMAN				WOMBAT-PK
Multidrug resistance-associated protein 4	Transporter	O15439	MRP4_HUMAN				WOMBAT-PK
Xanthine dehydrogenase/oxidase	Enzyme	P47989	XDH_HUMAN		IC50	4.03	CHEMBL
Hypoxanthine-guanine phosphoribosyltransferase	Enzyme	P00492	HPRT_HUMAN				WOMBAT-PK
Mitogen-activated protein kinase 3	Kinase	P27361	MK03_HUMAN		IC50	5.26	DRUG MATRIX
Prostaglandin G/H synthase 1	Enzyme	P23219	PGH1_HUMAN		IC50	6.22	DRUG MATRIX
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	4.91	DRUG MATRIX
Arachidonate 15-lipoxygenase	Enzyme		LOX15_RABIT		IC50	4.79	DRUG MATRIX

Showing 1 to 10 of 12 entries

Previous1 2Next

External reference:

Show entries

Search:

ID	Source
002652	NDDF
10485	RXNORM
2109	MMSL
2723601	PUBCHEM_CID
387407006	SNOMEDCT_US
4018777	VUID
4018777	VANDF
5569	MMSL
5580-03-0	SECONDARY_CAS_RN
6845	IUPHAR_LIGAND_ID

Showing 1 to 10 of 21 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
TABLOID	HUMAN PRESCRIPTION DRUG LABEL	1	69784-630	TABLET	40 mg	ORAL	NDA	23 sections
TABLOID	HUMAN PRESCRIPTION DRUG LABEL	1	69784-630	TABLET	40 mg	ORAL	NDA	23 sections
TABLOID	HUMAN PRESCRIPTION DRUG LABEL	1	76388-880	TABLET	40 mg	ORAL	NDA	23 sections
TABLOID	HUMAN PRESCRIPTION DRUG LABEL	1	76388-880	TABLET	40 mg	ORAL	NDA	23 sections
TABLOID	HUMAN PRESCRIPTION DRUG LABEL	1	80725-630	TABLET	40 mg	ORAL	NDA	23 sections

Showing 1 to 5 of 5 entries

Previous1Next